A 68-year-old male with COPD on mechanical ventilation for 5 days develops fever, purulent sputum, and a new infiltrate on chest X-ray. Gram stain shows gram-negative rods. Culture grows Pseudomonas aeruginosa susceptible to all antipseudomonal agents. What is the drug of choice for ventilator-associated pneumonia caused by P. aeruginosa?

Explanation

## Drug of Choice for Pseudomonas aeruginosa Respiratory Infection ### Rationale for Combination Therapy **Key Point:** P. aeruginosa respiratory infections (especially VAP) require dual antipseudomonal coverage — a β-lactam PLUS an aminoglycoside — to reduce mortality and prevent resistance emergence. **High-Yield:** The standard first-line regimen for P. aeruginosa VAP is: - **Piperacillin-tazobactam** (4.5 g IV q6h) OR - **Ceftazidime** (2 g IV q8h) OR - **Fluoroquinolone** (ciprofloxacin 400 mg IV q8h) **PLUS** an aminoglycoside (gentamicin or tobramycin for synergy and CNS penetration in severe infection). ### Why Combination? 1. **Synergistic bactericidal activity** — β-lactam damages cell wall; aminoglycoside enhances penetration and inhibits protein synthesis. 2. **Reduced resistance** — dual agents lower the risk of selecting resistant mutants during therapy. 3. **Improved outcomes** — mortality reduction in severe P. aeruginosa infections (especially sepsis, VAP, bacteremia). ### Antibiotic Spectrum Comparison | Agent | P. aeruginosa Coverage | Typical Use | Limitation | |-------|------------------------|-------------|------------| | Piperacillin-tazobactam | Excellent | First-line (β-lactam/β-lactamase inhibitor) | Resistance if used alone | | Ceftazidime | Excellent | First-line (3rd-gen cephalosporin) | Resistance if used alone | | Ciprofloxacin | Good | Oral step-down or mild infection | Inferior to β-lactam in severe disease | | Aminoglycoside | Excellent | Adjunct for synergy | Nephrotoxicity, ototoxicity | | Azithromycin | Poor | NOT for P. aeruginosa | Intrinsic resistance | | TMP-SMX | Poor | NOT for P. aeruginosa | Intrinsic resistance | ### Clinical Pearl **Warning:** Monotherapy with any single antipseudomonal agent (even ceftazidime alone) is associated with higher failure rates and emergence of resistance in VAP. Always combine a β-lactam with an aminoglycoside for serious infections. **Mnemonic:** **PITA** — **P**iperacillin + **I**mipenem + **T**azobactam + **A**minoglycoside = first-line for severe P. aeruginosa. ### Duration - VAP: 7–8 days (shorter courses reduce antibiotic exposure without compromising outcomes). - Adjust based on clinical response and susceptibilities.